Table 3.
Treatment outcome of enzyme replacement therapy in 91 surgically treated patients with chronic pancreatitis and pancreatic cancer and 91 non-operated patients
| Operated patients | Non-operated patients | |||
|---|---|---|---|---|
| All N = 91 | Chronic pancreatitis N = 54 (59 %) | Pancreatic cancer N = 37 (41 %) | All N = 91 | |
| Enzyme dose/daya; 25 % of patients | ≤3 | ≤4 | ≤3 | ≤3 |
| 50 % of patients | ≤6 | ≤6 | ≤5 | ≤4 |
| 75 % of patients | ≤8 | ≤8 | ≤7 | ≤6 |
| Symptoms of steatorrhea—n (%) | 62 (68) | 37 (69) | 25 (68) | 61 (67) |
| Weight loss—n (%) | 36 (39) | 19 (35) | 17 (46) | 35 (39) |
| Fat restriction—n (%) | 44 (48) | 28 (52) | 16 (43) | 52 (57) |
| Referral to dietician—n (%) | 33 (36) | 14 (26) | 19 (51) | 21 (23) |
aNumber of enteric-coated capsules containing 25,000 FIP units of lipase